The annual meeting of the American College of Obstetricians and Gynecologists was held virtually this year from April 30 to May 2 and attracted participants from around the world, including clinicians, academicians, allied health professionals, and others interested in obstetrics and gynecology. The conference highlighted recent advances in the prevention, detection, and treatment of conditions impacting women, with presentations focusing on the advancement of health care services for women worldwide.
In one study, Eran Bornstein, M.D., of Northwell Health in New York City, and colleagues found a significant association between neonatal birth weight and the likelihood of a successful external cephalic version (ECV).
The authors analyzed the U.S. Centers for Disease Control and Prevention Natality live birth database between 2016 and 2018. Data on all singleton, term, and live births with a birth weight of 2,500 to 5,000 g and an ECV attempt were included in the analyses (controlled for several potential confounders). Of the 11,150,527 live births in 2016 to 2018, 26,255 women who underwent an ECV attempt met the inclusion criteria. The researchers found that high birth weight was associated with higher ECV success rates (69 percent success rate in the 4,500- to 5,000-g group with 2.1 odds for success). Low birth weight was associated with lower ECV success rates (47 percent success rate in the 2,500- to 3,000-g group with 0.8 odds for success).
“This information is contrary to prior concerns that ECV is less likely to be successful with larger fetuses and may be used by providers while counseling patients regarding ECV,” Bornstein said.
In another study, Kaitlyn Mayer, M.D., of the Virginia Commonwealth University Medical Center in Richmond, and colleagues found a statistically significant decrease in time from induction to delivery with combination therapy of mifepristone and misoprostol compared to misoprostol alone for patients with late pregnancy loss.
The authors performed a systematic review to assess the efficacy of mifepristone with misoprostol compared to misoprostol alone for induction of labor due to intrauterine fetal demise in the third trimester of pregnancy. The researchers found that mifepristone administered prior to misoprostol for patients choosing medical management of pregnancy loss in the third trimester shortened induction-to-delivery intervals.